Entering text into the input field will update the search result below

Merck's Keytruda shows treatment effect in mid-stage liver cancer study

Jan. 19, 2018 7:10 AM ETMerck & Co., Inc. (MRK) StockBy: Douglas W. House, SA News Editor5 Comments
  • Results from a Phase 2 clinical trial, KEYNOTE-224, assessing Merck's (NYSE:MRK) PD-1 inhibitor KEYTRUDA (pembrolizumab) in patients with advanced hepatocellular carcinoma who were previously treated with Bayer's NEXAVAR (sorafenib) showed a treatment benefit. The data will be presented today at the ASCO-GI Symposium in San Francisco.
  • Patients treated with KEYTRUDA alone showed a 16.3% (n=17/104) overall response rate (ORR), the primary endpoint. The complete response rate was 1% (n=1/104) and the partial response rate was 15.4% (n=16/104).
  • Median duration of response at the time of analysis was 8.2 months with 94% of responses at least six months. The disease control rate (responders + those with stable disease) was 61.5% (n=64/104). Median progression-free survival (PFS) was 4.8 months. Median overall survival (OS) had not been reached at the time of analysis.
  • KEYTRUDA's safety profile was consistent with previous studies.
  • Shares are up a fraction premarket.

Recommended For You

About MRK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRK--
Merck & Co., Inc.